Orchestra BioMed Holdings, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Orchestra BioMed announced on October 1, 2026 that the BACKBEAT Global Pivotal Trial for AVIM Therapy (Atrioventricular Interval Modulation) surpassed its full enrollment target of 316 randomized patients, reaching 330 patients randomized across 81 sites in 13 countries as of September 30, 2026. The trial is evaluating AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension; primary endpoint data will be submitted for late-breaking presentation at a major cardiovascular conference in Q2 2027, with regulatory submissions to follow if results are positive. The strategic collaborator is Medtronic plc, which will handle commercialization subject to regulatory approval.
Why this rating
Enrollment milestone is significant for a $63.4M company dependent on single pivotal trial; de-risks critical path to regulatory submission and Medtronic partnership value realization, though outcome remains uncertain.
Tradability signal
NO TRADE
No trade: positive news with only +1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=139). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $6.23 | +10 min · unknown $6.25 ▲ 0.32% | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.